Dina iki, National Comprehensive Cancer Network® (NCCN®) nerbitake nganyari penting babagan rekomendasi konsensus ahli babagan vaksinasi lan profilaksis pra-paparan COVID-19 ing wong sing nandhang kanker. Komite Penasihat NCCN babagan Vaksinasi COVID-19 lan Profilaksis Pra-paparan kerep ketemu kanggo mriksa kabeh riset sing kasedhiya lan nyedhiyakake praktik paling apik adhedhasar bukti kanggo njaga wong sing nandhang kanker kanthi aman sajrone pandemi COVID-19. Pandhuan sing dianyari-kasedhiya ing NCCN.org/covid-19-kalebu informasi babagan panggunaan pencegahan antibodi monoklonal manungsa saliyane prinsip ing ngisor iki:
• Pasien kanker kudu diimunisasi kanthi lengkap, kalebu dosis katelu lan / utawa boosters sing disetujoni;
• Ana pilihan kuwat kanggo vaksin mRNA;
• Vaksinasi kudu ditundha paling sethithik 3 sasi sawise transplantasi sel hematopoietik (HCT) utawa terapi seluler sing direkayasa (contone, sel T reseptor antigen chimeric [CAR]) kanggo ngoptimalake khasiat vaksin. Penundaan vaksin ing pasien kanker uga kudu kalebu sing disaranake kanggo masarakat umum (contone, paparan COVID-19, terapi Ab monoklonal anyar);
• Vaksinasi lengkap uga dianjurake kanggo pengasuh, kontak kluwarga / cedhak, lan masyarakat umum;
• Panitia banget ndhukung mandat vaksinasi lengkap kanggo buruh kesehatan.
Administrasi Pangan lan Narkoba (FDA) wis ngetokake wewenang panggunaan darurat kanggo kombinasi antibodi monoklonal tixagevimab plus cilgavimab kanggo proteksi pra-paparan saka COVID-19 ing wong diwasa lan bocah wiwit umur 12 (bobot paling sethithik 40 kg) sing duwe moderat. kanggo kompromi imun sing abot lan bisa uga ora responsif kanggo vaksinasi. Pasien sing nandhang kanker getih (kalebu sing nampa transplantasi sel induk utawa terapi seluler sing direkayasa) luwih cenderung duwe respon sing ora nyukupi kanggo vaksinasi COVID-19 lan duwe risiko komplikasi COVID-19 sing paling dhuwur. Panitia kasebut nyatakake yen cukup prioritas kanggo pasien kasebut kanggo tixagevimab plus cilgavimab sadurunge pasien kanker tumor sing padhet yen ana pasokan sing winates.
Panitia uga ndhukung rekomendasi saka Centers for Disease Control (CDC), American Society of Transplantation and Cellular Therapy (ASTCT), lan American Society of Hematology (ASH) sing sadurunge divaksinasi pasien sing ngrampungake transplantasi sel induk utawa terapi seluler sing direkayasa kudu nampa a baleni seri vaksinasi wiwit telung sasi sawise perawatan.
Komite Penasihat NCCN babagan Vaksinasi COVID-19 lan Profilaksis Pra-eksposur dumadi saka dokter multidisiplin terkemuka saka kabeh Institusi Anggota NCCN, kanthi keahlian khusus babagan penyakit infèksius, pangembangan lan pangiriman vaksin, manajemen kanker, lan etika medis. NCCN bakal terus nganyari Rekomendasi kanggo adaptasi karo owah-owahan kahanan, kalebu akeh akeh bukti.
Kabeh rekomendasi NCCN kanggo perawatan kanker sajrone pandemi bisa ditemokake ing NCCN.org/covid-19. Pandhuan pasien lan caregiver kanggo vaksinasi uga kasedhiya ing NCCN.org/patientguidelines.
APA sing kudu dijupuk saka ARTIKEL INI:
- The Food and Drug Administration (FDA) has issued an emergency use authorization for the monoclonal antibody combination of tixagevimab plus cilgavimab for pre-exposure protection from COVID-19 in adults and children starting at age 12 (weighing at least 40 kg) who have moderate to severe immune compromise and may not be responsive to vaccination.
- Panitia uga ndhukung rekomendasi saka Centers for Disease Control (CDC), American Society of Transplantation and Cellular Therapy (ASTCT), lan American Society of Hematology (ASH) sing sadurunge divaksinasi pasien sing ngrampungake transplantasi sel induk utawa terapi seluler sing direkayasa kudu nampa a baleni seri vaksinasi wiwit telung sasi sawise perawatan.
- The NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis meets frequently to review all available research and provide evidence-based best practices for keeping people with cancer as safe as possible during the COVID-19 pandemic.
